SEC 13F Intelligence

Managers / Q1 2022 · view latest →

Altium Capital Management LLC

CIK 0001746382 · 152 W 57 ST FL7, NEW YORK, NY, 10019 · 2124842711

Reported Value
$299M
Q1 2022
Positions
118
Filings on Record
25
2019–present window
Filed
May 16, 2022
original filing

Summary

Altium Capital Management LLC reported $299M in U.S.-listed holdings across 118 positions for Q1 2022.

Its largest position, ESPR, represents 3.9% of the portfolio.

Compared with Q4 2021, the fund opened 32 new positions and exited 48.

Portfolio Metrics

Turnover
+28.4%
vs prior filed quarter
Top-10 Concentration
+26.4%
share of reported value
Largest Position
+3.9%
Esperion Therapeutics Inc Ne
New / Exited
32 / 48
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $268MQ4 ’20Q1 ’21: $360MQ2 ’21: $431MQ3 ’21: $381MQ3 ’21Q4 ’21: $363MQ1 ’22: $299MQ2 ’22: $250MQ2 ’22Q3 ’22: $273MQ4 ’22: $197MQ1 ’23: $180MQ1 ’23Q2 ’23: $132MQ3 ’23: $192MQ4 ’23: $147MQ4 ’23Q1 ’24: $253MQ2 ’24: $245MQ3 ’24: $340MQ3 ’24Q4 ’24: $353MQ1 ’25: $42MQ2 ’25: $0Q2 ’25Q3 ’25: $628,262Q4 ’25: $25MQ1 ’26: $42MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 75.2%Other: 21.5%ADR: 2.7%Equity WRT: 0.6%
  • Common Stock · 75.2% · $225M
  • Other · 21.5% · $64M
  • ADR · 2.7% · $8M
  • Equity WRT · 0.6% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
PEPPERLIME HEALTH ACQUSTN CONEW+735.0K735.0K+$7M$7M
DXCMDEXCOM INCNEW+12.5K12.5K+$6M$6M
TNDMTANDEM DIABETES CARE INCNEW+50.0K50.0K+$6M$6M
NVSTENVISTA HOLDINGS CORPORATIONNEW+105.0K105.0K+$5M$5M
SHOCKWAVE MED INCNEW+23.0K23.0K+$5M$5M
KARYOPHARM THERAPEUTICS INCNEW+645.0K645.0K+$5M$5M
IMMUNOGEN INCNEW+920.0K920.0K+$4M$4M
LIVNLIVANOVA PLCNEW+50.0K50.0K+$4M$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2022

102 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ESPRESPERION THERAPEUTICS INC NEhistory →COM3.88%$12M2.50M
2BLUBELLUS HEALTH INC NEWhistory →COM NEW3.34%$10M1.45M
3PTGXPROTAGONIST THERAPEUTICS INChistory →COM3.06%$9M386.0K
4CHINOOK THERAPEUTICS INCCOM2.98%$9M545.0K
5PEPPERLIME HEALTH ACQUSTN COUNIT 99/99/9999 · *W EXP 10/01/2022.47%$7M1.10M
6KROSKEROS THERAPEUTICS INChistory →COM2.29%$7M126.0K
7DXCMDEXCOM INChistory →COM2.14%$6M12.5K
8QUIDEL CORPCOM2.11%$6M56.0K
9INSMINSMED INChistory →COM PAR $.012.11%$6M268.0K
10ADMAADMA BIOLOGICS INChistory →COM2.02%$6M3.30M
11GMEDGLOBUS MED INChistory →CL A1.95%$6M79.0K
12TNDMTANDEM DIABETES CARE INChistory →COM NEW1.95%$6M50.0K
13NEVRO CORPCOM1.86%$6M77.0K
14RLMDRELMADA THERAPEUTICS INChistory →COM1.86%$6M206.0K
15CYMABAY THERAPEUTICS INCCOM1.82%$5M1.75M
16GKOSGLAUKOS CORPhistory →COM1.82%$5M94.0K
17BCYCBICYCLE THERAPEUTICS PLChistory →SPONSORED ADS1.76%$5M120.0K
18NOCTURNE ACQUISITION CORPORDINARY SHARES · RIGHT 12/26/20251.72%$5M1.00M
19NVSTENVISTA HOLDINGS CORPORATIONhistory →COM1.71%$5M105.0K
20SHOCKWAVE MED INCCOM1.60%$5M23.0K
21KARYOPHARM THERAPEUTICS INCCOM1.59%$5M645.0K
22QGENQIAGEN NVhistory →SHS NEW1.53%$5M93.0K
23AVIDITY BIOSCIENCES INCCOM1.50%$4M243.0K
24CRNXCRINETICS PHARMACEUTICALS INhistory →COM1.50%$4M204.0K
25IMMUNOGEN INCCOM1.47%$4M920.0K
26XTNTXTANT MED HLDGS INChistory →COM NEW1.42%$4M6.25M
27VERASTEM INCCOM1.39%$4M2.95M
28INSPINSPIRE MED SYS INChistory →COM1.37%$4M16.0K
29LIVNLIVANOVA PLChistory →SHS1.37%$4M50.0K
30IVERIC BIO INCCOM1.33%$4M236.0K
31EUCRATES BIOMEDICAL ACQU CORSHS · *W EXP 10/23/2021.33%$4M533.3K
32ILMNILLUMINA INChistory →COM1.29%$4M11.0K
331847 GOEDEKER INC*W EXP 06/02/2021.26%$4M6.10M
34EIGER BIOPHARMACEUTICALS INCCOM1.22%$4M440.0K
35OCULOCULAR THERAPEUTIX INChistory →COM1.15%$3M695.0K
36IMMUNIC INCCOM1.13%$3M300.0K
37ADICET BIO INCCOM1.04%$3M155.0K
38MYGNMYRIAD GENETICS INCCOM0.97%$3M114.7K
39KRMDREPRO MED SYS INCCOM0.95%$3M995.5K
40EYPTEYEPOINT PHARMACEUTICALS INCCOM NEW0.91%$3M224.5K
41KARUNA THERAPEUTICS INCCOM0.89%$3M21.0K
42TURMERIC ACQUISITION CORPCL A · *W EXP 10/08/2020.85%$3M338.7K
43MORPHIC HLDG INCCOM0.81%$2M60.0K
44OMGBPOUTSET MED INCCOM0.79%$2M52.0K
45HLMNHILLMAN SOLUTIONS CORPCOM0.78%$2M196.0K
46SARISSA CAPITAL ACQUISITN COCL A · *W EXP 10/23/2020.75%$2M300.0K
47CLDXCELLDEX THERAPEUTICS INC NEWCOM NEW0.75%$2M66.0K
48LNTHLANTHEUS HLDGS INCCOM0.74%$2M40.0K
49SLNSILENCE THERAPEUTICS PLCADS0.69%$2M109.0K
50LAKESHORE ACQUISITION I CORPORDINARY SHARES · *W EXP 07/15/2020.68%$2M350.0K
51GIGINTERNATIONAL1 INCCOM · *W EXP 04/19/2020.68%$2M250.0K
52CHAVANT CAPITAL ACQUISITN COORDINARY SHARES · *W EXP 99/99/9990.67%$2M350.0K
53CARA THERAPEUTICS INCCOM0.67%$2M165.0K
54TG VENTURE ACQUISITION CORPUNIT 08/15/20280.67%$2M200.0K
55JIYA ACQUISITION CORPCOM CL A0.66%$2M200.0K
562SEVENTY BIO INCCOMMON STOCK0.66%$2M115.0K
57ALTALTIMMUNE INCCOM NEW0.66%$2M322.0K
58AGIOAGIOS PHARMACEUTICALS INCCOM0.64%$2M66.2K
59RENOVACOR INCCOM · *W EXP 99/99/9990.64%$2M1.12M
60GLOBAL BLOOD THERAPEUTICS INCOM0.63%$2M54.0K
61PARDES BIOSCIENCES INCCOM0.61%$2M253.0K
62CTMXCYTOMX THERAPEUTICS INCCOM0.59%$2M663.8K
63PRCTPROCEPT BIOROBOTICS CORPCOM0.55%$2M47.1K
64DIGITAL HEALTH ACQUISITION CUNIT 11/02/20260.51%$2M150.0K
65AULT DISRUPTIVE TECHS CORPCOM · *W EXP 99/99/9990.51%$2M262.5K
66SOMALOGIC INCCLASS A COM0.48%$1M180.0K
67CTI BIOPHARMA CORPCOM0.47%$1M299.8K
68INTRA-CELLULAR THERAPIES INCCOM0.46%$1M22.5K
69CURIS INCCOM NEW0.43%$1M540.8K
70TAILWIND ACQUISITION CORPCOM CL A0.43%$1M128.4K
71PROFPROFOUND MED CORPCOM NEW0.38%$1M124.9K
72CUTERA INCCOM0.35%$1M15.0K
73FAT BRANDS INC*W EXP 07/16/2020.34%$1M227.0K
74INDUSTRIAL HUMAN CAPITAL INCCOM · *W EXP 11/27/2020.34%$1M200.0K
75MURPHY CANYON ACQUISITION COUNIT 01/25/20270.34%$1M100.0K
76RELATIVITY ACQUISITION CORPUNIT 02/10/20270.34%$1M100.0K
77WESTERN ACQSTN VENTURES CORPUNIT 09/01/20260.33%$1M100.0K
78OPY ACQUISITION CORP ICOM CL A · *W EXP 09/22/2020.33%$1M150.0K
79BCLS ACQUISITION CORPCOM CL A0.33%$987,000100.0K
80OMEGA ALPHA SPACCL A0.33%$982,000100.0K
81ARYA SCIENCES ACQU CORP IVCL A0.33%$980,000100.0K
82MUSCLE MAKER INCCOM0.32%$948,0001.80M
83ACHVACHIEVE LIFE SCIENCES INCCOM0.31%$924,000122.0K
84COLISEUM ACQUISITION CORPCLASS A ORD SHS · *W EXP 08/22/2020.28%$835,000113.3K
85VQSSFVIQ SOLUTIONS INCCOM NEW0.27%$798,000489.4K
86VERRICA PHARMACEUTICALS INCCOM0.27%$794,00097.9K
87DDIDOUBLEDOWN INTERACTIVE CO LTADS0.24%$722,00060.9K
88GSR II METEORA ACQUISITN CORUNIT 02/24/20270.17%$506,00050.0K
89COLOMBIER ACQUISITION CORPCL A · *W EXP 99/99/9990.16%$489,00066.7K
90TCBWFTC BIOPHARM HOLDINGS PLC*W EXP 02/08/2020.15%$461,000941.2K
91HARBOR CUSTOM DEVELOPMENT IN*W EXP 10/04/202 · *W EXP 05/09/2020.14%$411,0001.25M
92LIGHTNING EMOTORS INC*W EXP 05/18/2020.09%$268,000652.2K
93SURGEPAYS INC*W EXP 10/22/2020.07%$223,000250.0K
94BNCWWCEA INDUSTRIES INC*W EXP 02/11/2020.06%$171,000250.0K
95IMMATICS N.V*W EXP 07/01/2020.06%$171,00097.5K
96DIRECT DIGITAL HOLDINGS INC*W EXP 02/15/2020.04%$131,000180.0K
97CINGWCINGULATE INC*W EXP 12/03/2020.04%$108,000270.0K
98HEALTH SCIENCES ACQ CORP 2ORD SHS0.03%$99,00010.0K
99NXGLWNEXGEL INC*W EXP 12/01/2020.03%$88,000225.0K
100CALITHERA BIOSCIENCES INCCOM0.03%$82,000202.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$42M19May 1, 202613F-HRchanges · EDGAR ↗
Q4 2025$25M18Feb 6, 202613F-HRchanges · EDGAR ↗
Q3 2025$628,2621Nov 4, 202513F-HRchanges · EDGAR ↗
Q2 2025$01Aug 7, 202513F-HRchanges · EDGAR ↗
Q1 2025$42M24May 13, 2025RESTATEMENTchanges · EDGAR ↗
Q4 2024$353M67Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$340M79Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$245M68Aug 15, 202413F-HRchanges · EDGAR ↗
Q1 2024$253M72May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$147M66Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$192M72Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$132M68Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$180M91May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$197M94Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$273M134Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$250M127Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$299M118May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$363M133Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$381M124Nov 17, 2021RESTATEMENTchanges · EDGAR ↗
Q2 2021$431M135Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$360M124May 6, 202113F-HRchanges · EDGAR ↗
Q4 2020$268M95May 5, 2021RESTATEMENTchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.